Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Ann H Klopp, Danielle Enserro, Matthew Powell, Marcus Randall, Julian C Schink, Robert S Mannel, Laura Holman, David Bender, Christina L Kushnir, Floor Backes, Susan L Zweizig, Steven Waggoner, Kristin A Bradley, Lana DeSouza Lawrence, Parviz Hanjani, Christopher J Darus, William Small, Higinia R Cardenes, Jonathan M Feddock, David S Miller
PURPOSE: Pelvic recurrence is a frequent pattern of relapse for women with endometrial cancer. A randomized trial compared progression-free survival (PFS) after treatment with radiation therapy alone as compared with concurrent chemotherapy. MATERIALS AND METHODS: Between February 2008 and August 2020, 165 patients were randomly assigned 1:1 to receive either radiation treatment alone or a combination of chemotherapy and radiation treatment. The primary objective of this study was to determine whether chemoradiation therapy was more effective than radiation therapy alone at improving PFS...
April 25, 2024: Journal of Clinical Oncology
#2
LETTER
Sheng Zhang, Wenfeng Li
No abstract text is available yet for this article.
April 24, 2024: Journal of Clinical Oncology
#3
JOURNAL ARTICLE
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Jörg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua Meeks, Francisco E Vera Badillo, J Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Grünwald, Michael Hölzel, Markus Eckstein
PURPOSE: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS: We established a NECTIN4 -specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108)...
April 24, 2024: Journal of Clinical Oncology
#4
JOURNAL ARTICLE
Nathaniel S O'Connell
No abstract text is available yet for this article.
April 24, 2024: Journal of Clinical Oncology
#5
LETTER
Subodh Selukar
No abstract text is available yet for this article.
April 24, 2024: Journal of Clinical Oncology
#6
JOURNAL ARTICLE
Cindy Im, Achal Neupane, Jessica L Baedke, Brian Lenny, Angela Delaney, Stephanie B Dixon, Eric J Chow, Sogol Mostoufi-Moab, Tianzhong Yang, Melissa A Richard, M Monica Gramatges, Philip J Lupo, Noha Sharafeldin, Smita Bhatia, Gregory T Armstrong, Melissa M Hudson, Kirsten K Ness, Leslie L Robison, Yutaka Yasui, Carmen L Wilson, Yadav Sapkota
PURPOSE: Type 2 diabetes mellitus (T2D) is a prevalent long-term complication of treatment in survivors of childhood cancer, with marked racial/ethnic differences in burden. In this study, we investigated trans-ancestral genetic risks for treatment-related T2D. PATIENTS AND METHODS: Leveraging whole-genome sequencing data from the St Jude Lifetime Cohort (N = 3,676, 304 clinically ascertained cases), we conducted ancestry-specific genome-wide association studies among survivors of African and European genetic ancestry (AFR and EUR, respectively) followed by trans-ancestry meta-analysis...
April 23, 2024: Journal of Clinical Oncology
#7
JOURNAL ARTICLE
Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika P Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger-Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric-Bernstam
PURPOSE: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker. PATIENTS AND METHODS: TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors...
April 23, 2024: Journal of Clinical Oncology
#8
JOURNAL ARTICLE
Christian Ekanger, Svein Inge Helle, Lars Reisæter, Liv Bolstad Hysing, Rune Kvåle, Alfred Honoré, Karsten Gravdal, Sara Pilskog, Olav Dahl
PURPOSE: There are no well-established re-treatment options for local recurrence after primary curative radiation therapy for prostate cancer (PCa), as prospective studies with long-term follow-up are lacking. Here, we present results from a prospective study on focal salvage reirradiation with external-beam radiation therapy with a median follow-up of 7.2 years. MATERIALS AND METHODS: From 2013 to 2017, 38 patients with biopsy-proven locally recurrent PCa >2 years after previous treatment and absence of grade 2-3 toxicity from the first course of radiation were included...
April 23, 2024: Journal of Clinical Oncology
#9
JOURNAL ARTICLE
David R Spigel, Afshin Dowlati, Yuanbin Chen, Alejandro Navarro, James Chih-Hsin Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Zoran G Andric, Yi-Long Wu, Charles M Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, Fawzi Benzaghou, Luis Paz-Ares, Paul A Bunn
PURPOSE: The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) liposomal irinotecan (70 mg/m2 every 2 weeks in a 6-week cycle) or IV topotecan (1.5 mg/m2 daily for 5 consecutive days, every 3 weeks in a 6-week cycle). The primary end point was overall survival (OS)...
April 22, 2024: Journal of Clinical Oncology
#10
REVIEW
Annelot J M Meijer, Franciscus A Diepstraten, Marc Ansari, Eric Bouffet, Archie Bleyer, Brice Fresneau, James I Geller, Alwin D R Huitema, Per Kogner, Rudolf Maibach, Allison F O'Neill, Vassilios Papadakis, Kaukab M Rajput, Gareth J Veal, Michael Sullivan, Marry M van den Heuvel-Eibrink, Penelope R Brock
PURPOSE: Hearing loss occurs in 50%-70% of children treated with cisplatin. Scientific efforts have led to the recent approval of a pediatric formula of intravenous sodium thiosulfate (STS) for otoprotection by the US Food and Drug Administration, the European Medicines Agency, and the Medicines and Health Regulatory Authority in the United Kingdom. To inform stakeholders regarding the clinical utility of STS, the current review summarizes available literature on the efficacy, pharmacokinetics (PK), and safety of systemic STS to minimize cisplatin-induced hearing loss (CIHL)...
April 22, 2024: Journal of Clinical Oncology
#11
JOURNAL ARTICLE
Robert S Fichtinger, Luca A Aldrighetti, Mohammed Abu Hilal, Roberto I Troisi, Robert P Sutcliffe, Marc G Besselink, Somaiah Aroori, Krishna V Menon, Bjørn Edwin, Mathieu D'Hondt, Valerio Lucidi, Tom F Ulmer, Rafael Díaz-Nieto, Zahir Soonawalla, Steve White, Gregory Sergeant, Bram Olij, Francesca Ratti, Christoph Kuemmerli, Vincenzo Scuderi, Frederik Berrevoet, Aude Vanlander, Ravi Marudanayagam, Pieter Tanis, Maxime J L Dewulf, Cornelis H C Dejong, Zina Eminton, Merel L Kimman, Lloyd Brandts, Ulf P Neumann, Åsmund A Fretland, Siân A Pugh, Gerard J P van Breukelen, John N Primrose, Ronald M van Dam
PURPOSE: To compare outcomes after laparoscopic versus open major liver resection (hemihepatectomy) mainly for primary or metastatic cancer. The primary outcome measure was time to functional recovery. Secondary outcomes included morbidity, quality of life (QoL), and for those with cancer, resection margin status and time to adjuvant systemic therapy. PATIENTS AND METHODS: This was a multicenter, randomized controlled, patient-blinded, superiority trial on adult patients undergoing hemihepatectomy...
April 19, 2024: Journal of Clinical Oncology
#12
EDITORIAL
Ann M Gillenwater, Nadarajah Vigneswaran, Andrew G Sikora
No abstract text is available yet for this article.
April 18, 2024: Journal of Clinical Oncology
#13
JOURNAL ARTICLE
Chengcheng Yan, Melissa A Richard, Christopher J Gibson, Jianbo He, Alysia Bosworth, David K Crossman, Purnima Singh, Lindsey Hageman, Rashi Kalra, Saro H Armenian, Julie Vose, Daniel J Weisdorf, Benjamin L Ebert, Yutaka Yasui, Stephen J Forman, Ravi Bhatia, Smita Bhatia
PURPOSE: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product and subsequent post-aPBSCT risk of t-MN in patients with non-HL, information about patients with HL treated with aPBSCT is not available. METHODS: We constructed a retrospective cohort of 321 patients with HL transplanted at a median age of 34 years (range, 18-71)...
April 18, 2024: Journal of Clinical Oncology
#14
JOURNAL ARTICLE
Christopher A Barker, Suzanne Dufault, Sarah T Arron, Alan L Ho, Alain P Algazi, Lara A Dunn, Audrey A Humphries, Carter Hultman, Ming Lian, P Daniel Knott, Sue S Yom
PURPOSE: Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI) active in BCC that may radiosensitize BCC. We evaluated the combination of vismodegib and RT for patients with LA BCC. METHODS: In this multicenter, single-arm, phase II study, patients with unresectable LA BCC received 12 weeks of induction vismodegib, followed by 7 weeks of concurrent vismodegib and RT...
April 17, 2024: Journal of Clinical Oncology
#15
JOURNAL ARTICLE
Douglas E Peterson, Nicole L Stout, Lawrence N Shulman, Jennifer Perkins, Gabrielle LeMarier, Larissa Nekhlyudov
Delivery of high-quality, evidence-based oral care for those living with and beyond cancer needed!
April 17, 2024: Journal of Clinical Oncology
#16
(no author information available yet)
No abstract text is available yet for this article.
April 16, 2024: Journal of Clinical Oncology
#17
REVIEW
Nicholas Mikolajewicz, Patricia P Yee, Debarati Bhanja, Mara Trifoi, Alexandra M Miller, Philippe Metellus, Stephen J Bagley, Leonora Balaj, Leonardo J M de Macedo Filho, Brad E Zacharia, Dawit Aregawi, Michael Glantz, Michael Weller, Manmeet S Ahluwalia, Thomas Kislinger, Alireza Mansouri
Effective diagnosis, prognostication, and management of CNS malignancies traditionally involves invasive brain biopsies that pose significant risk to the patient. Sampling and molecular profiling of cerebrospinal fluid (CSF) is a safer, rapid, and noninvasive alternative that offers a snapshot of the intracranial milieu while overcoming the challenge of sampling error that plagues conventional brain biopsy. Although numerous biomarkers have been identified, translational challenges remain, and standardization of protocols is necessary...
April 12, 2024: Journal of Clinical Oncology
#18
JOURNAL ARTICLE
Anne Tierens, Nira Arad-Cohen, Daniel Cheuk, Barbara De Moerloose, Jose Maria Fernandez Navarro, Henrik Hasle, Kirsi Jahnukainen, Kristian Løvvik Juul-Dam, Gertjan Kaspers, Zanna Kovalova, Birgitte Lausen, Ulrika Norén-Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Bernward Zeller, Jonas Abrahamsson
PURPOSE: Measurable residual disease (MRD) by using flow cytometry after induction therapy is strongly prognostic in pediatric AML, and hematopoietic stem-cell transplant (hSCT) may counteract a poor response. We designed a phase III study with intensified response-guided induction and MRD-based risk stratification and treated poor induction response with hSCT. The efficacy of liposomal daunorubicin (DNX) in induction was compared with mitoxantrone. METHODS: The study planned to randomly assign 300 patients, but the production of DNX ceased in 2017...
April 11, 2024: Journal of Clinical Oncology
#19
JOURNAL ARTICLE
Sarah Alexander, John A Kairalla, Sumit Gupta, Emily Hibbitts, Hannah Weisman, Doralina Anghelescu, Naomi J Winick, Kevin R Krull, Wanda L Salzer, Michael J Burke, Lia Gore, Meenakshi Devidas, Leanne Embry, Elizabeth A Raetz, Stephen P Hunger, Mignon L Loh, Kristina K Hardy
PURPOSE: Many children treated for ALL develop long-term neurocognitive impairments. Increased risk of these impairments is associated with treatment and demographic factors. Exposure to anesthesia is an additional possible risk factor. This study evaluated the impact of cumulative exposure to anesthesia on neurocognitive outcomes among a multicenter cohort of children with ALL. METHODS: This study was embedded in AALL1131, a Children's Oncology Group phase III trial for patients with high-risk B-ALL...
April 11, 2024: Journal of Clinical Oncology
#20
JOURNAL ARTICLE
Alejandro Ríos-Hoyo, Erin Cobain, Laura A Huppert, Peter D Beitsch, Thomas A Buchholz, Laura Esserman, Laura J van 't Veer, Hope S Rugo, Lajos Pusztai
No abstract text is available yet for this article.
April 9, 2024: Journal of Clinical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
